{"log_id": 5371769601984817302, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.000169, "average": 0.987463, "min": 0.960106}, "location": {"width": 155, "top": 196, "height": 34, "left": 274}, "words": "【临床试验】"}, {"probability": {"variance": 0.011944, "average": 0.945025, "min": 0.53753}, "location": {"width": 1107, "top": 237, "height": 61, "left": 294}, "words": "在228例中、重度活动性类凤湿性关节炎患者参加的随机双盲、甲氨呤对照、多中心"}, {"probability": {"variance": 0.021029, "average": 0.929162, "min": 0.351935}, "location": {"width": 1126, "top": 308, "height": 59, "left": 262}, "words": "研究中,患者接受了24周的治疗,其中试验组接受益赛普ing/次,每周2次皮下注射治疗"}, {"probability": {"variance": 0.028911, "average": 0.883888, "min": 0.386243}, "location": {"width": 1137, "top": 370, "height": 63, "left": 264}, "words": "对照组接受口服氨蝶呤治疗。疗效评价采港AC2疗效评定标准结果显示,在茫"}, {"probability": {"variance": 0.037361, "average": 0.892483, "min": 0.406128}, "location": {"width": 806, "top": 445, "height": 52, "left": 269}, "words": "行2周后益赛普组ACR20有效率为35.59,疗显于对照组"}, {"probability": {"variance": 0.011785, "average": 0.920267, "min": 0.729855}, "location": {"width": 203, "top": 438, "height": 38, "left": 1201}, "words": "治疗12周后,"}, {"probability": {"variance": 0.022471, "average": 0.872121, "min": 0.435246}, "location": {"width": 1137, "top": 502, "height": 61, "left": 264}, "words": "赛普组ACR20有效率为66.10,行效明显优手对照组(P0.05治疗4周后,益赛音组ACE20"}, {"probability": {"variance": 0.030427, "average": 0.890127, "min": 0.357212}, "location": {"width": 1137, "top": 568, "height": 61, "left": 264}, "words": "有效率为80.39,ACR70有效也优于对照组P0.上一主要的药物不臭反应有注射部位"}, {"probability": {"variance": 0.020471, "average": 0.913959, "min": 0.423798}, "location": {"width": 982, "top": 634, "height": 61, "left": 267}, "words": "反应、皮,转氨酶升高感染等,感染发生率在两组中比较没有显著性差异"}, {"probability": {"variance": 0.027086, "average": 0.895433, "min": 0.352413}, "location": {"width": 1107, "top": 701, "height": 59, "left": 269}, "words": "在14例中重度斑状银屑病患者参加的随机双育,甲氨蝶呤对照,多中心临不研究中"}, {"probability": {"variance": 0.01137, "average": 0.943265, "min": 0.477774}, "location": {"width": 1139, "top": 767, "height": 59, "left": 269}, "words": "患者受了12周的治疗,其中试验组接受益赛普2a0g次,每周2次皮下注射治疗:对照组接"}, {"probability": {"variance": 0.033621, "average": 0.86191, "min": 0.424979}, "location": {"width": 1139, "top": 833, "height": 59, "left": 269}, "words": "受口报甲氨蝶治疗,疗效评价采用PASI、PA、DLI及患者点病情整体评分:疗兹分析采"}, {"probability": {"variance": 0.023098, "average": 0.918669, "min": 0.451893}, "location": {"width": 1135, "top": 897, "height": 61, "left": 271}, "words": "用PS150175/50评分结果显示,从第周开始益赛音的治疗效果明显优于对照到治疗"}, {"probability": {"variance": 0.035941, "average": 0.86086, "min": 0.407073}, "location": {"width": 1137, "top": 963, "height": 59, "left": 269}, "words": "第12周时,益普组的患老达到PA315075/30的七侧为:3.3%、83.%、56.67%:疗"}, {"probability": {"variance": 0.037939, "average": 0.863974, "min": 0.363691}, "location": {"width": 1130, "top": 1027, "height": 61, "left": 274}, "words": "效时显干对照(<心05冶疗12周后,急青益费雪都能运好的耐受不良反应发生"}, {"probability": {"variance": 0.012685, "average": 0.93723, "min": 0.536551}, "location": {"width": 493, "top": 1107, "height": 47, "left": 269}, "words": "率低,程度轻,和对照比较没有差开"}, {"probability": {"variance": 0.035153, "average": 0.863721, "min": 0.398897}, "location": {"width": 1135, "top": 1162, "height": 59, "left": 274}, "words": "在11例活动性强三性脊柱执患者参加的能机双育、安慰剂对照、多中心的临床研究中,"}, {"probability": {"variance": 0.029551, "average": 0.906837, "min": 0.402285}, "location": {"width": 1137, "top": 1228, "height": 59, "left": 274}, "words": "者接受12周的济疗:其中分为2个段:在前6周的双对照治疗价,试验患考接受益赛"}, {"probability": {"variance": 0.01596, "average": 0.941404, "min": 0.42355}, "location": {"width": 1121, "top": 1295, "height": 57, "left": 276}, "words": "25mg,每周2次皮下注射,对照组使用交慰剂。该阶段结束后进八后6周开放治行阶段"}, {"probability": {"variance": 0.012194, "average": 0.936935, "min": 0.4605}, "location": {"width": 1119, "top": 1359, "height": 61, "left": 276}, "words": "两江都使用益赛,药量同上e疗效评价采用ASAS20评价标准,结果显示,在双盲对照阶段"}, {"probability": {"variance": 0.03066, "average": 0.900245, "min": 0.392344}, "location": {"width": 1107, "top": 1427, "height": 54, "left": 276}, "words": "治疗2周和6周时益赛普ASAS2C的比例为5507%和6.12%,明显伏于安剂(P<0.01)"}, {"probability": {"variance": 0.027139, "average": 0.893863, "min": 0.446853}, "location": {"width": 1135, "top": 1493, "height": 54, "left": 276}, "words": "益赛普连续治疗12周时达到ASAS2O的比例是78.2安慰剂组在开放期经过6周益赛普治疗"}, {"probability": {"variance": 0.012819, "average": 0.946012, "min": 0.402581}, "location": {"width": 1132, "top": 1557, "height": 57, "left": 278}, "words": "后,达到ASAS20的比例是7%,疗效明显。研究中患者对益赛都能很好的耐受。在双盲对"}, {"probability": {"variance": 0.013363, "average": 0.96002, "min": 0.370229}, "location": {"width": 1137, "top": 1624, "height": 57, "left": 276}, "words": "照阶段,益赛不良反应发生率和安慰剂比较无显著差异。发生的不良反应程度轻,不需要"}, {"probability": {"variance": 0.000506, "average": 0.985356, "min": 0.934798}, "location": {"width": 319, "top": 1701, "height": 45, "left": 274}, "words": "特别治疗,可以自行恢复"}, {"probability": {"variance": 0.039342, "average": 0.898033, "min": 0.456754}, "location": {"width": 153, "top": 1811, "height": 36, "left": 294}, "words": "【药理赤理】"}, {"probability": {"variance": 0.07631, "average": 0.832204, "min": 0.353787}, "location": {"width": 116, "top": 1877, "height": 34, "left": 312}, "words": "药作用"}, {"probability": {"variance": 0.026062, "average": 0.923703, "min": 0.37013}, "location": {"width": 1135, "top": 1925, "height": 59, "left": 278}, "words": "已知痛坏死因子(TNF-a)是类风湿性关节炎、银屑病强直性脊柱炎等病理过中的一个"}, {"probability": {"variance": 0.008674, "average": 0.961729, "min": 0.58781}, "location": {"width": 1130, "top": 1994, "height": 54, "left": 280}, "words": "主要炎性介质,其参与谓控的炎症反应可导致关节的病理改变:本品的作用机制为竞争性地"}, {"probability": {"variance": 0.024441, "average": 0.901473, "min": 0.442813}, "location": {"width": 810, "top": 2064, "height": 50, "left": 283}, "words": "与血中TNF-a结合,阻断它和细胞表面TNF受体结合,降任其活性"}], "language": 3}